PFE - Olema Pharmaceuticals: Still Merits A Small Holding

2024-06-17 11:58:18 ET

Summary

• Olema Pharmaceuticals is focused on developing palazestrant and OP-3136 for women with cancer, with FDA Fast Track designation for palazestrant.
• Palazestrant is currently being evaluated in a Phase 3 clinical trial for ER+/HER2- advanced or metastatic breast cancer and as part of combination therapies.
• Analyst firms have reissued Buy ratings for Olema in June following trial updates, and the company's balance sheet is solid for now.
• An updated analysis around Olema Pharmaceuticals follows in the paragraphs below.

Today, we are circling back to an oncology-focused clinical-stage developmental concern called Olema Pharmaceuticals, Inc. ( OLMA ). Our last article on Olema was posted just after Thanksgiving Day last year. We concluded that piece noting the stock merited a small ' watch item ' holding and we would revisit Olema in the near future. The stock got a bit of a boost earlier this month when Pfizer Inc. ( PFE ) posted positive study results around a similar candidate that Olema is pursuing. An updated analysis follows below....

For further details see: